Patents Assigned to Wake Forest University
  • Patent number: 10676529
    Abstract: Provided herein are monoclonal antibodies that specifically bind IL-13RA2 with cross-reactivity in humans and canines. Also provided are methods of use of the antibodies in the treatment and monitoring of cancers.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: June 9, 2020
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Denise Mazess Herpai
  • Patent number: 10572999
    Abstract: Methods, systems, computer programs, circuits and workstations are configured to generate at least one two-dimensional weighted CBF territory map of color-coded source artery locations using an automated vascular segmentation process to identify source locations using mutual connectivity in both image and label space.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: February 25, 2020
    Assignee: Wake Forest University Health Sciences
    Inventor: Youngkyoo Jung
  • Patent number: 10562844
    Abstract: Provided herein are compounds of Formula (I), Formula (II), and Formula (III), and compositions comprising the same, as well as methods of use thereof for controlling or inhibiting the formation of calcium oxalate kidney stones, inhibiting the production of glyoxylate and/or oxalate, and/or inhibiting hydroxyproline dehydrogenase (HYPDH).
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: February 18, 2020
    Assignees: Wake Forest University Health Sciences, UAB Research Foundation
    Inventors: W. Todd Lowther, Ross P. Holmes, Daniel Yohannes
  • Patent number: 10547006
    Abstract: In one aspect, composite layers are described herein demonstrating phase-separated architectures which, in some embodiments, can mitigate performance disadvantages of prior organic layers of optoelectronic devices. A composite organic layer described herein comprises nanocluster nodes and carbon nanoparticles disposed in a conjugated polymeric host, wherein the carbon nanoparticles are substantially phase separated from the conjugated polymeric host forming lamellar structures of carbon nanofibrils radiating from the nanocluster nodes.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: January 28, 2020
    Assignee: Wake Forest University
    Inventor: David Carroll
  • Patent number: 10537689
    Abstract: Provided herein is a delivery system, including: (a) an optical sensor configured to detect data to create a map of a patient bodily surface; and (b) a dispenser operatively associated with the optical sensor and configured to deliver compositions (optionally including cells) to the patient bodily surface based upon the data or map. Methods of forming a tissue on a patient bodily surface of a patient in need thereof are also provided, as are methods, systems and computer program products useful for processing patient bodily surface data.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: January 21, 2020
    Assignee: Wake Forest University Health Sciences
    Inventors: James J. Yoo, Anthony Atala, Kyle W. Binder, Mohammad Z. Albanna, Weixin Zhao, Dennis Dice, Tao Xu
  • Patent number: 10519210
    Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: December 31, 2019
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
  • Patent number: 10512690
    Abstract: The present invention relates to nanoparticle compositions and, in particular, to composite polymeric nanoparticle compositions. A composite nanoparticle described herein comprises a photoluminescent polymeric component and a photo-thermal polymeric component. The photoluminescent polymeric component and the photo-thermal polymeric component can each comprise a single polymeric species or multiple polymeric species.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: December 24, 2019
    Assignee: Wake Forest University
    Inventors: Nicole Hope Levi, Christopher Michael MacNeill, Elizabeth Grace Gurysh, Louis Charles Argenta
  • Publication number: 20190375860
    Abstract: Modified alginates are described herein along with hydrogels comprising the same. A modified alginate may be prepared by reacting alginate and an aromatic compound (e.g., an aromatic amine) and/or pH sensitive compound. The modified alginates, hydrogels, and/or methods described herein may be used to coat and/or encapsulate at least a portion of a bioactive substance, optionally for oral delivery in humans and other animals.
    Type: Application
    Filed: June 30, 2017
    Publication date: December 12, 2019
    Applicants: Wake Forest University Health Sciences, Wake Forest University
    Inventors: Mark E. WELKER, Emmanuel C. OPARA, Surya R. BANKS, Amber N. WEISSENENFLUH
  • Patent number: 10500384
    Abstract: Provided herein is a delivery system, including: (a) an optical sensor configured to detect data useful to create a map of a bodily surface; and (b) a printer operatively associated with the optical sensor and configured to deliver compositions (optionally including cells) to the bodily surface based upon the data or map. Methods of forming a tissue on a bodily surface of a patient in need thereof are also provided, as are methods, systems and computer program products useful for processing bodily surface data.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: December 10, 2019
    Assignee: Wake Forest University Health Sciences
    Inventors: James J. Yoo, Anthony Atala, Kyle W. Binder, Weixin Zhao, Dennis Dice, Tao Xu
  • Patent number: 10493041
    Abstract: A method of treating hypoxic tissue such as wound tissue comprises contacting a composition to the hypoxic tissue in a hypoxia-treatment effective amount, the composition comprising a biodegradable polymer and an inorganic peroxide incorporated into the polymer.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: December 3, 2019
    Assignee: Wake Forest University Health Sciences
    Inventors: Benjamin C. Harrison, James J. Yoo, Anthony Atala
  • Patent number: 10493040
    Abstract: A method of treating hypoxic tissue such as wound tissue comprises contacting a composition to the hypoxic tissue in a hypoxia-treatment effective amount, the composition comprising a biodegradable polymer and an inorganic peroxide incorporated into the polymer.
    Type: Grant
    Filed: April 8, 2008
    Date of Patent: December 3, 2019
    Assignee: Wake Forest University Health Sciences
    Inventors: Benjamin S. Harrison, James J. Yoo, Anthony Atala
  • Patent number: 10481153
    Abstract: Methods, systems, devices and apparatus for use in screening and/or selecting a library of nucleic acid molecules and/or nucleic acid tagged or encoded molecules for binding to or interaction with a target molecule or substance (e.g., for use in new compound or drug discovery) are described. In some embodiments the device comprises: (a) a spatially addressable array, said array comprising a plurality of separate and discrete locations thereon; (b) a plurality of different oligomers operably connected to said spatially addressable array at different ones of said separate and discrete locations; (c) a tag sequence which is complementary to, and is hybridized to, each of said oligomers; and (d) a candidate chemical operably connected to each of said tag sequences, wherein each of said discrete locations is a unique identifier for its corresponding oligomer; and wherein said tag sequence is a unique identifier for its connected candidate chemical.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: November 19, 2019
    Assignees: Wake Forest University, NanoMedica LLC
    Inventors: Keith Bonin, Jed C. Macosko, Jason Gagliano, Martin Guthold, Roger Cubicciotti
  • Patent number: 10449388
    Abstract: Disclosed herein are systems and methods for specifying treatment criteria and treatment planning parameters for patient specific radiation therapy planning. According to an aspect, a method includes receiving data about a patient, computing geometric characterization of one or more organs at risk proximate to a target volume of a patient or vice versa, and selecting relevant treatment knowledge and experience. The method also includes generating, based on the received data, computed geometric characterization, and available knowledge and experience, a first set of radiation treatment planning parameters that will lead to a high quality plan for the patient. Further, the method includes model-based prediction, based on the data, a second set or more of radiation treatment planning parameters that will lead to alternative achievable plans with different organ sparing objectives for treating the patient. The multiple sets for parameters can be used separately or in conjunction to generate treatment plans.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: October 22, 2019
    Assignees: Duke University, Wake Forest University Health Sciences
    Inventors: Fang-Fang Yin, Qingrong Jackie Wu, Lulin Yuan, Yaorong Ge
  • Patent number: 10443105
    Abstract: The present invention provides methods of assessing an individual subject's risk of developing prostate cancer, comprising: a) analyzing a nucleic acid sample obtained from the subject and determining a genotype for the subject at a plurality of biallelic polymorphic loci, wherein each of said plurality has an associated allele and an unassociated allele, wherein the genotype is selected from the group consisting of homozygous for the associated allele, heterozygous, and homozygous for the unassociated allele; and b) calculating a cumulative relative risk (CRR) for the subject based on the genotype determined in step (a). A CRR of greater than 1.00 identifies a subject as having an increased risk of developing prostate cancer and also can identify a subject who is a candidate for early PSA screening, prostate biopsy and/or chemoprevention.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: October 15, 2019
    Assignee: Wake Forest University Health Sciences
    Inventors: Jianfeng Xu, Siqun Lilly Zheng, Jielin Sun, Andrew Karim Kader
  • Patent number: 10434213
    Abstract: Provided herein are keratin compositions (e.g., keratin gels, scaffolds, particulates, and the like) including a compound of interest, useful for release and/or delivery of the compound of interest (e.g., in vivo or in vitro). In some embodiments, the composition is a composition formulated for controlled release of the compound of interest.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: October 8, 2019
    Assignee: Wake Forest University Health Sciences
    Inventors: Mark E. Van Dyke, Justin M. Saul, Thomas L. Smith, Roche de Guzman
  • Patent number: 10420818
    Abstract: A method of treating a sphincter deficiency disorder (e.g., incontinence; gastrointestinal disorders) is carried out by administering stromal cell-derived factor 1 (SDF-1) to a sphincter or sphincter complex, such as a urethral or gastrointestinal sphincter (e.g., a rectal sphincter) of the subject in a treatment-effective amount.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: September 24, 2019
    Assignee: Wake Forest University Health Sciences
    Inventor: James K. Williams
  • Patent number: 10398739
    Abstract: A composition comprising microcapsules, the microcapsules containing both live mammalian ovarian granulosa cells and live mammalian ovarian theca cells, is described. In some embodiments, the granulosa cells and the theca cells are contained in separate microcapsules in the composition; in some embodiments, the granulosa cells and the theca cells are contained together in the same microcapsules in the composition. The composition is can be used for estrogen, and optionally also progesterone, delivery, and hence is preferably free or essentially free of oocytes. Methods of using the same and pharmaceutical formulations containing the same are also described.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: September 3, 2019
    Assignee: Wake Forest University Health Sciences
    Inventors: Emmanuel C. Opara, James J. Yoo, Justin M. Saul, Sittadjody Sivanandane, Anthony Atala
  • Patent number: 10398804
    Abstract: Provided herein are urine progenitor cells and methods for producing a culture of urine progenitor cells from a urine sample. The cells may be selected based upon the use of a selective cell medium, based upon morphology, and/or by selecting cell-specific markers. Also provided is an isolated urine progenitor cell that is c-kit positive and can differentiate into urothelium, smooth muscle, endothelium or interstitial cells. Methods of use of urine progenitor cells are provided, wherein cell are seeded onto a tissue scaffold are provided. Methods of treating a subject in need thereof are also provided, including providing a bladder tissue substrate that includes differentiated UPCs and transplanting the substrate into the patient. Finally, kits are provided that include a container suitable for the transport of a urine sample; media; one or more antibiotics; a package for holding said container, media, and antibiotics; and optionally, instructions for use.
    Type: Grant
    Filed: May 20, 2008
    Date of Patent: September 3, 2019
    Assignee: Wake Forest University Health Sciences
    Inventors: Yuanyuan Zhang, Anthony Atala
  • Patent number: 10309956
    Abstract: A process for assessing risk that administration of a substance will suppress immune competence in a population of subjects is provided. Such a substance may be a substance related to, contained in or derived from a tobacco product or, more generally, a substance concerning which it is desired to assess risk of administration of the substance.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: June 4, 2019
    Assignees: R.J. Reynolds Tobacco Company, Wake Forest University Health Sciences
    Inventors: Gaddamanugu L. Prasad, Subhashini Arimilli
  • Patent number: D852375
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: June 25, 2019
    Assignee: Wake Forest University Health Sciences
    Inventors: John David Druga, Sr., Philip Jayson Brown, Aaron Van Gorkom